Tal Zaks, Exsilio Therapeutics chairman and interim CEO

Can mR­NA be har­nessed for gene in­ser­tion? Mod­er­na's for­mer chief med­ical of­fi­cer has $82M to find out

Exsilio Ther­a­peu­tics has raised $82 mil­lion in hopes of us­ing mR­NA to sur­mount the lim­i­ta­tions of cur­rent gene ther­a­pies.

mR­NA is a medi­um that the …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.